CME vs NDAQ

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 09, 2026

CME

46.6
AI Score
VS
CME Wins

NDAQ

44.1
AI Score

Investment Advisor Scores

CME

47score
Recommendation
HOLD

NDAQ

44score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CME NDAQ Winner
Revenue 3.59B 4.67B NDAQ
Net Income 2.20B 1.03B CME
Net Margin 61.2% 22.0% CME
Operating Income 2.42B 1.37B CME
ROE 8.3% 8.6% NDAQ
ROA 1.1% 3.8% NDAQ
Total Assets 194.68B 27.34B CME
Cash 2.14B 520.00M CME
Current Ratio 1.02 1.01 CME
Free Cash Flow 2.16B 1.26B CME

Relative Price Performance (Last 90 Days)

CME 1M: +5.1% · 3M: +5.1% NDAQ 1M: -4.7% · 3M: +5.1%

Current Technical Phase

CME

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (4.9% over 20 days), RSI 53

RSI (14): 53.1 · Price: $275.54

NDAQ

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 35

RSI (14): 35.3 · Price: $91.19

Fundamentals Snapshot

Metric CME NDAQ
Market Cap
Forward P/E 21.3 19.5
Trailing P/E 23.3 26.8
Revenue (TTM)
Revenue Growth 0.0% 0.1%
Gross Margin 1.0% 1.0%
Operating Margin 0.7% 0.5%
EPS 11.78 3.43
Dividend Yield 0.02% 0.01%

Frequently Asked Questions

Based on our detailed analysis, CME is currently the stronger investment candidate, winning 7 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.